Challenges in orphan drug development and regulatory policy in China-Reference-Cited by-同舟云学术

Challenges in orphan drug development and regulatory policy in China

Published:2017-01-18 Issue:1 Volume:12 Page:
ISSN:1750-1172
Container-title:Orphanet Journal of Rare Diseases
language:en
Short-container-title:Orphanet J Rare Dis

Author:

Cheng Alice,Xie Zhi

Funder

Whitaker International Fellows and Scholars Program

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Genetics (clinical),General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13023-017-0568-6.pdf

Reference49 articles.

1. Huang Z: Baidu, China’s version of Google, is “evil,” a growing number of users say. In Quartz. http://qz.com/674030/baidu-chinas-version-of-google-is-evil-a-growing-number-of-users-say/ . Accessed 10 Jan 2017.

2. Yin C, Jing M: Baidu ordered to overhaul its healthcare ads. In China Daily http://europe.chinadaily.com.cn/business/2016-05/10/content_25191508_2.htm . Accessed 10 Jan 2017.

3. Wang JB, Guo JJ, Yang L, Zhang YD, Sun ZQ, Zhang YJ. Rare diseases and legislation in China. Lancet. 2010;375:708–9.

4. RARE diseases: Facts and statistics. Global Genes. https://globalgenes.org/rare-diseases-facts-statistics/ . Accessed 10 Jan 2017.

5. Evaluate Ltd. Orphan drug report 2014. London: Evaluate Ltd.; 2014.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmaceutical policy and innovation for rare diseases: A narrative review;F1000Research;2023-11-13

2. Investigation of the diagnostic importance and accuracy of CT in the chest compared to the RT-PCR test for suspected COVID-19 patients in Jordan;F1000Research;2023-11-13

3. Analysis on the Marketing Trend and Approval Lag of Imported Orphan Drugs from 2010 to 2021 in China;Therapeutic Innovation & Regulatory Science;2023-08-31

4. Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications;Orphanet Journal of Rare Diseases;2023-07-27

5. Is sub-national healthcare social protection sufficient for protecting rare disease patients? the case of China;Frontiers in Public Health;2023-06-16